Comparative Effectiveness for AI MedTech

Comparative Effectiveness for AI MedTech

Comparative Effectiveness for AI MedTechNicole Coustier
Published on: 04/09/2024

Why comparing your AI MedTech solution to the status quo isn’t enough for payer approval.

Evidence Planning
AI MedTech Reimbursement: Insights from Recent Literature

AI MedTech Reimbursement: Insights from Recent Literature

AI MedTech Reimbursement: Insights from Recent LiteratureNicole Coustier
Published on: 13/08/2024

A review of what peer-reviewed publications reveal about payer adoption of AI tools.

Payer Coverage
The Myth of ‘Build First, Worry Later’: Why Early Reimbursement Strategy is the Key to MedTech Survival

The Myth of ‘Build First, Worry Later’: Why Early Reimbursement Strategy is the Key to MedTech Survival

The Myth of ‘Build First, Worry Later’: Why Early Reimbursement Strategy is the Key to MedTech SurvivalNicole Coustier
Published on: 03/08/2024

Why U.S. reimbursement strategy should begin long before FDA approval if you want to survive.

Commercialization Planning
Relearning English When it Comes to FDA and CMS Jargon

Relearning English When it Comes to FDA and CMS Jargon

Relearning English When it Comes to FDA and CMS JargonNicole Coustier
Published on: 04/06/2024

MedTech teams often misunderstand what regulators mean. This article translates FDA and CMS jargon into actionable insights for reimbursement.

U.S. Healthcare FundamentalsFeatured